Prothena Corporation plc (PRTA)
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
What Makes Prothena (PRTA) a New Buy Stock
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago.
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
Eli Lilly stock reversed premarket gains at the open Tuesday after an FDA panel endorsed its Alzheimer's treatment, donanemab.
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
